The stock of LeMaitre Vascular Inc (NASDAQ:LMAT) is a huge mover today! About 105,421 shares traded hands. LeMaitre Vascular Inc (NASDAQ:LMAT) has risen 47.53% since April 14, 2016 and is uptrending. It has outperformed by 42.84% the S&P500.
The move comes after 7 months positive chart setup for the $438.07M company. It was reported on Nov, 16 by Barchart.com. We have $54.20 PT which if reached, will make NASDAQ:LMAT worth $565.11 million more.
LeMaitre Vascular Inc (NASDAQ:LMAT) Ratings Coverage
Out of 9 analysts covering LeMaitre Vascular (NASDAQ:LMAT), 8 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 89% are positive. LeMaitre Vascular has been the topic of 22 analyst reports since July 29, 2015 according to StockzIntelligence Inc. Roth Capital maintained LeMaitre Vascular Inc (NASDAQ:LMAT) rating on Tuesday, May 3. Roth Capital has “Buy” rating and $18.50 price target. The stock of LeMaitre Vascular Inc (NASDAQ:LMAT) has “Buy” rating given on Monday, December 7 by Dougherty & Company. The company was initiated on Thursday, September 10 by Barrington Research. The firm earned “Neutral” rating on Wednesday, January 20 by Sidoti. The rating was maintained by Benchmark with “Buy” on Wednesday, July 29. The stock of LeMaitre Vascular Inc (NASDAQ:LMAT) has “Buy” rating given on Wednesday, July 29 by TH Capital. The stock has “Outperform” rating given by Cowen & Co on Thursday, April 21. The rating was maintained by TH Capital with “Buy” on Monday, December 7. The stock has “Outperform” rating given by Barrington Research on Thursday, February 25. On Friday, December 4 the stock rating was maintained by Stifel Nicolaus with “Buy”.
According to Zacks Investment Research, “LEMAITRE VASCULAR, INC. is a leading global provider of innovative devices for the treatment of peripheral vascular disease. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre’s diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time.”
Insitutional Activity: The institutional sentiment decreased to 1.24 in Q2 2016. Its down 0.79, from 2.03 in 2016Q1. The ratio is negative, as 6 funds sold all LeMaitre Vascular Inc shares owned while 31 reduced positions. 12 funds bought stakes while 34 increased positions. They now own 10.35 million shares or 1.88% more from 10.16 million shares in 2016Q1.
Moreover, Ameriprise Financial has 0% invested in LeMaitre Vascular Inc (NASDAQ:LMAT) for 75,909 shares. Goldman Sachs Grp last reported 35,872 shares in the company. New York State Common Retirement Fund last reported 10,900 shares in the company. Blackrock Institutional Comm Na holds 259,143 shares or 0% of its portfolio. Schwab Charles Inv Mngmt holds 38,776 shares or 0% of its portfolio. Bridgeway Cap Inc owns 50,200 shares or 0.01% of their US portfolio. Automobile Association has invested 0.01% of its portfolio in LeMaitre Vascular Inc (NASDAQ:LMAT). The Washington-based Parametric Portfolio Associate Limited Company has invested 0% in LeMaitre Vascular Inc (NASDAQ:LMAT). Moreover, Blackrock Invest Management Lc has 0% invested in LeMaitre Vascular Inc (NASDAQ:LMAT) for 48,752 shares. Bnp Paribas Arbitrage has invested 0% of its portfolio in LeMaitre Vascular Inc (NASDAQ:LMAT). The Pennsylvania-based Pnc Fincl Ser Gru has invested 0% in LeMaitre Vascular Inc (NASDAQ:LMAT). Wedge Mngmt L L P Nc reported 52,000 shares or 0.01% of all its holdings. Blackrock Japan Limited accumulated 1,821 shares or 0% of the stock. First Light Asset Mngmt Ltd Liability holds 2.55% of its portfolio in LeMaitre Vascular Inc (NASDAQ:LMAT) for 385,562 shares. Diam Ltd accumulated 0% or 8,740 shares.
Insider Transactions: Since May 20, 2016, the stock had 0 buys, and 24 sales for $7.29 million net activity. On Tuesday, August 2 LeMaitre George W sold $80,124 worth of the stock or 4,540 shares. Another trade for 5,000 shares valued at $85,733 was sold by LeMaitre Cornelia W. Shares for $539,207 were sold by Gebauer Peter R. Jasinski Lawrence J also sold $132,001 worth of LeMaitre Vascular Inc (NASDAQ:LMAT) shares. 10,000 shares were sold by Roberts David B, worth $176,332. 1,524 shares were sold by Kamke Trent G, worth $23,248.
LMAT Company Profile
LeMaitre Vascular, Inc., incorporated on June 15, 1998, is a well-known provider of medical devices for the treatment of peripheral vascular disease. The Firm and its subsidiaries develop, manufacture and market medical devices and implants used primarily in the field of vascular surgery. It operates in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment. The Company’s product lines include valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, prosthetic vascular grafts, biologic vascular grafts and powered phlebectomy devices. The Company’s portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, VascuTape Radiopaque Tape and the XenoSure biologic patch. The Company’s principal product offerings are sold across the world, primarily in the United States, Europe, Asia and the Pacific Rim. The Company’s subsidiaries include LeMaitre Vascular GmbH, LeMaitre Vascular GK, Vascutech Acquisition LLC, LeMaitre Acquisition LLC, LeMaitre Vascular SAS, LeMaitre Vascular S.r.l., LeMaitre Vascular Spain SL, LeMaitre Vascular Switzerland GmbH, LeMaitre Vascular ULC, LeMaitre Vascular AS, LeMaitre Vascular Pty Ltd, and Xenotis Pty Ltd.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.